Show simple item record

TACTI-002: a phase II study of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic NSCLC

dc.contributor.authorForster, M.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorMajem, M.
dc.contributor.authorPeguero, J.
dc.contributor.authorClay, T.
dc.contributor.authorFelip, E.
dc.contributor.authorIams, W.
dc.contributor.authorRoxburgh, P.
dc.contributor.authorDoger, B.
dc.contributor.authorBajaj, P.
dc.contributor.authorKefas, J.
dc.contributor.authorScott, J. A.
dc.contributor.authorJoaquin, A. B.
dc.contributor.authorMueller, C.
dc.contributor.authorTriebel, F.
dc.date.accessioned2022-11-30T10:21:21Z
dc.date.available2022-11-30T10:21:21Z
dc.date.issued2022en
dc.identifier.citationForster M, Krebs M, Majem M, Peguero J, Clay T, Felip E, et al. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. Journal of Thoracic Oncology. 2022 Sep;17(9):S395-S. PubMed PMID: WOS:000858678101128.en
dc.identifier.doi10.1016/j.jtho.2022.07.681en
dc.identifier.urihttp://hdl.handle.net/10541/625782
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2022.07.681en
dc.titleTACTI-002: a phase II study of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic NSCLCen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUCL Cancer Institute / University College London Hospitals NHS Foundation, Londonen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record